Media Coverage
Back to Media CoverageMix of opinion on Vertex deal; Sigilon coming on strong
Enter Sigilon, where therapeutics consist of human cells engineered to produce the proteins, enzymes or factors needed by patients with hemophilia, diabetes and lysosomal storage disorders (LSDs).